Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-<i>Versus</i>-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide.

We also detected an increasing trend to increase in the levels of CD3 + HLA-DR + , CD4, and CD8 T-cells in the LTV-treated compared with the LTV-untreated PTCy-haplo patients (median HLA-DR + activated T-cells:150/μL vs . 59/μL, p = 0.079, CD4 + and CD8 + T-cells are shown in Table 2 ).

also in 63,971 other papers